Trial Profile
A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Circassia; Niox
- 25 Feb 2013 Two-year results have been presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) according to a Circassia media release. Results were also reported in the media release.
- 13 Sep 2012 Results published in the Journal of Allergy and Clinical Immunology.
- 25 May 2012 Two-year extension study record identified and integrated (ClinicalTrials.gov record NCT01604018).